Crossmark

A phase II trial evaluating the effects and intra-tumoral penetration of bortezomib in patients with recurrent malignant gliomas

Crossref DOI link: https://doi.org/10.1007/s11060-016-2156-3

Published Online: 2016-06-14

Published Print: 2016-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Raizer, Jeffrey J.

Chandler, James P.

Ferrarese, Roberto

Grimm, Sean A.

Levy, Robert M.

Muro, Kenji

Rosenow, Joshua

Helenowski, Irene

Rademaker, Alfred

Paton, Martin

Bredel, Markus
Funding

Funding for this research was provided by:

Mellenium Pharmaceutical
License Information

License valid from 2016-06-14